$137.00
You’ll be briefly redirected to Link Money, our secure ACH payment partner, to connect your bank and complete payment.– Your bank login is never visible to or stored by us – Encrypted, bank-level security – A standard, trusted payment process
In laboratory environments, CJC-1295 with DAC is studied to investigate sustained growth hormone releasing hormone signaling and its effects on endocrine communication networks. Researchers frequently analyze how extended receptor activation within the pituitary gland influences growth hormone release and downstream signaling pathways.
Experimental studies often focus on prolonged endocrine signaling models, allowing investigation into how long-acting GHRH analogs influence hormonal feedback systems and cellular communication. These models are commonly used to study relationships between growth hormone, metabolic signaling, and regulatory pathways within endocrine systems.
Scientific literature also explores how sustained activation of GHRH receptors impacts signaling networks associated with cellular growth, metabolic processes, and endocrine regulation. These investigations remain confined strictly to laboratory research contexts and do not represent approved therapeutic applications.
CJC 1295 with DAC is used in laboratory research to study prolonged GH releasing hormone activity, endocrine feedback loops, and hormone release dynamics. Researchers evaluate its role as a GH secretagogue and GHRH analog when examining sustained GH secretion, GH pulse patterns, and receptor signaling mechanisms.
The DAC component—also referred to as a drug affinity complex—allows the CJC 1295 DAC peptide to bind reversibly to serum albumin in research models. This DAC modification supports extended peptide exposure, fewer frequent injections, and reduced frequent dosing during experimental protocols, compared to shorter-acting mod GRF or modified GRF compounds.
No. While both are forms of CJC 1295, CJC 1295 w DAC is designed for prolonged activity, whereas non-DAC variants are studied for shorter-duration GH release. This distinction allows researchers to compare GH levels, IGF 1 levels, and natural GH pulses under different timing and exposure conditions.
In research settings, injection, subcutaneous injection, and dosing are terms commonly referenced when describing experimental delivery methods. However, Aion Aminos does not provide instructions, recommendations, or guidance for dosing, injection, or reconstitution. This CJC 1295 peptide therapy-related terminology appears strictly in an academic or experimental context and does not imply approved use.
